Nektar Therapeutics has turned a recaptured regulatory T-cell biologic into a funded late-stage dermatology franchise, and that is the entire investment case. Rezpegaldesleukin, an interleukin-two pathway agonist designed to expand regulatory T cells, entered the global ZENITH AD program in July after a large Phase 2b study met its primary and secondary endpoints. Cash and investments exceeded $1 billion at mid-year, enough, management says, to carry the company past the first atopic dermatitis readout. The market is paying a mid-cap multiple for a wholly owned mechanism that still has no product sales and a first biologics license application target late in the decade.
The financing was expensive in share-count terms. A reverse split in mid-2025 reset the capital structure after years of partner-driven collapse. Successive offerings in February and April then lifted the fully diluted base above thirty-four million shares. The April follow-on priced at $92 a share. Gross proceeds reached $374 million. That raise, stacked on a February secondary and an at-the-market facility, rebuilt liquidity. What the raise bought is time, not proof. Atopic dermatitis is already occupied by Dupixent and a growing interleukin-thirteen class. The Phase 2b investigator global assessment rate of twenty percent versus eight percent on placebo is clinically real but not class-leading. Alopecia areata is the cleaner commercial opening because Janus kinase inhibitors carry boxed warnings. The Phase 2b primary endpoint still missed statistical significance in the full modified intent-to-treat set.
The next two years resolve a simple question. Either rezpegaldesleukin enrolls and retains a large pivotal atopic dermatitis program with a safety and durability profile that can win share from incumbents, or the long wait exposes the equity to competitive readouts and a rising burn as research spending steps toward a full-year budget above $200 million. A Lilly breach-of-contract trial running in a California federal court is a separate, asymmetric overlay. It is not the thesis.